http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Glycan and glycosaminoglycans as clinical biomarkers and therapeutics
Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B, Volume 163 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include an Overview of Fugal Glycan-based Therapeutics, Heparin: An Essential Drug for Modern Medicine, Low Molecular Weight Heparins and Their Clinical Applications, The Clinical Use of Fondaparinux: A Synthetic Heparin Pentasaccharid, Heparinoids as Clinically Used Drugs, Marine Glycan-Derived Therapeutics in China, Efficacy of Heparinoid PSS in Treating Cardiovascular and other Diseases-30 Years Clinical Applications in China, and more.
Front Cover; Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics -- Part B; Copyright; Contents; Contributors; Preface; Chapter One: Heparin: An essential drug for modern medicine; 1. Introduction; 2. Structure of heparin; 3. The mechanisms of the heparin; 4. Clinical studies of heparin; 4.1. Anti-coagulation activity of heparin; 4.2. Anti-cancer activity of heparin; 4.3. Heparin in inflammatory diseases; 4.4. Heparin in infectious disease; 4.5. Other diseases; 5. Concluding remarks; Acknowledgments; References
Chapter Two: Low molecular weight heparins and their clinical applications1. Introduction; 2. Structure of LMWHs; 3. Clinical uses of LMWHs; 4. Update on the LMWHs under clinic trials and its potential applications; 4.1. Anti-tumor; 4.2. Anti-viral; 4.3. Anti-inflammation; 4.4. Anti-diabetes-associated complications; 4.5. Other applications; 5. Concluding remarks; Acknowledgments; References; Chapter Three: The clinical use of Fondaparinux: A synthetic heparin pentasaccharide; 1. Structure and mechanism of Fondaparinux; 2. Pharmacokinetics and pharmacodynamics of Fondaparinux
3. Clinical application of Fondaparinux3.1. Prophylaxis of VTE; 3.2. Prophylaxis of DVT; 3.3. Other clinical indications; 4. Concluding remarks; Acknowledgments; Conflict of interest; References; Chapter Four: Heparinoids Danaparoid and Sulodexide as clinically used drugs; 1. Heparin and heparinoids; 2. Heparin, low molecular weight heparin, Danaparoid and Sulodexide; 3. Clinical applications of Danaparoid; 3.1. Danaparoid in HIT; 3.2. Danaparoid in DVT; 3.3. Danaparoid in DIC; 4. Clinical applications of Sulodexide; 4.1. Anticoagulant and antithrombotic activity
4.2. Prevention of reperfusion injury4.3. Sulodexide in other diseases; 5. Concluding remarks; Acknowledgments; References; Chapter Five: Efficacy of heparinoid PSS in treating cardiovascular diseases and beyond-A review of 31 years clinical exp ... ; 1. Introduction; 2. Preparation, chemical structure, and clinical doses; 3. Clinical uses and efficacy; 4. Adverse reactions; 5. Pharmacodynamics; 6. Pharmacokinetics; 7. Future perspectives; Acknowledgment; Conflicts of interest; References; Chapter Six: Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies
1. Introduction2. Preparation and structure of fucoidan; 3. Pharmacology and mechanism of fucoidan; 3.1. Chronic renal failure (CRF); 3.2. Acute kidney injury (AKI); 3.3. Diabetic nephropathy (DN); 4. Clinical uses and efficacy of fucoidan; 5. Future perspectives; Acknowledgments; References; Chapter Seven: Marine glycan-derived therapeutics in China; 1. Introduction; 2. Fucoidan (Haikunshenxi capsules); 2.1. Chemical structure and preparation; 2.2. Pharmacological activities; 2.3. Clinical applications; 3. Chitin ester (PS916); 3.1. Pharmacological activities; 3.2. Pharmacokinetics
Includes bibliographical references and index.
Progress in molecular biology and translational science ; v. 163